(B) Central to peripheral deposition (C/P) ratio in moderate and mild cystic fibrosis lungs
Methods: This study randomized 151 patients with CF with chronic PA infection to one of three doses of MP-376 (120 mg every day, 240 mg every day, 240 mg twice a day) or
We evaluated the efficacy of inhaled levofloxacin solution in 86 patients with cystic fibrosis in terms of the following outcome parameters: changes in
Levofloxacin is a well-known antibiotic, and
We present a patient with cystic fibrosis who used nebulized levofloxacin off-label to suppress chronic Burkholderia cenocepacia pulmonary infection
Pulmonary infections caused by Pseudomonas aeruginosa (PA) represent the leading cause of pulmonary morbidity in adults with cystic fibrosis (CF)
Chronic pulmonary infections are common among patients with cystic fibrosis
Inhaled antibiotics, i
There have been significant improvements in both delivery devices and the formulation of drugs with “intelligent
Ten CF subjects received single 180-mg doses of two formulations of MP-376, followed by a multiple-dose phase of 240 mg once daily for 7 days
Methods: Patients completing a multinational, randomized study comparing
People with cystic fibrosis (CF) are highly susceptible to bacterial infections of the airways
for the Mpex 204 Study Group (2010) Effects of inhaled MP-376 (Aeroquin, levofloxacin inhalation solution) on lung function in stable cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) lung infection [abstract]
, a global biopharmaceutical company focused on the development and commercialization of transformative therapeutics for rare, debilitating and often fatal diseases, recently announced it has acquired the rights to Quinsair™ (levofloxacin inhalation solution) from Tripex Pharmaceuticals
, 2015 Flume P
Chronic pulmonary infections are common among patients with cystic fibrosis
C
Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled